Anixa Biosciences, Inc. ANIX 深 滬
等待開盤 03-26 09:30:00 美东时间
2.70
+0.110
+4.25%
華盛通- 最 高2.83
- 今 開2.64
- 成交量 13.16万股
- 最 低 2.56
- 昨 收 2.59
- 總市值 9052.52万
- 52周最高 5.4566
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.331
- 委 比 64.49%
- 總股本 3352.79万
- 歷史最高 8.09
- 量 比 1.13
- 振 幅 10.42%
- 歷史最低 1.33
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
03-12 22:38
BRIEF-Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress
BRIEF-Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress March 2 (Reuters) - Anixa Biosciences Inc ANIX.O : ANIXA BIOSCIENCES TO HOST 2026 ANNUAL MEETING OF STOCKHOLDERS AND PROVIDE CORPORATE UPDATE HIGHLIGH
03-02 22:11
Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat
Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat Anixa Biosciences said Duke University School of Medicine immunology professor Jose Conejo-Garcia, co-inventor of its FSHR-mediated CAR-T technology, will deliver a keynote at the South Carolina Clinical & Translati
02-23 21:55
Anixa Biosciences startet Phase-1-Studie mit hoher CAR-T-Dosis bei Eierstockkrebs
Anixa Biosciences startet Phase-1-Studie mit hoher CAR-T-Dosis bei Eierstockkrebs Anixa Biosciences Inc. hat ein Update zur laufenden Phase-1-Studie einer CAR-T-Zelltherapie bei Eierstockkrebs bekanntgegeben. Das Unternehmen berichtet, dass mehrere Patientinnen in den niedrigen Dosierungsgruppen ein
02-09 21:01
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.
02-09 20:31
美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
02-04 21:03
Anixa Biosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting
Anixa Biosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting Anixa Biosciences Inc. will hold its annual meeting virtually on March 10, 2026. During the meeting, shareholders will be asked to vote on the election of director nominees to serve on the company's board, the approval on
01-29 05:17
BUZZ-U.S. STOCKS ON THE MOVE-Sysco, Corning, HCA Healthcare
BUZZ-U.S. STOCKS ON THE MOVE-Sysco, Corning, HCA Healthcare Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and Nasdaq advanced on Tuesday as investors parsed through a s
01-27 23:45
BUZZ-Anixa Biosciences rises after Mexico approves patent for breast cancer vaccine
BUZZ-Anixa Biosciences rises after Mexico approves patent for breast cancer vaccine ** Shares of San Jose-based cancer treatment developer Anixa Biosciences ANIX.O up 7.47% at $3.32 premarket ** Co says Mexican Institute of Industrial Property approved a patent for its experimental breast cancer vac
01-27 22:02
